| 摘要 |
Disclosed is a composition comprising an amount of pharmaceutical-grade ferric citrate having an intrinsic dissolution rate of 1.9 to 4.0 mg/cm2/min, and a BET active surface area exceeding 16 m2/g. Also disclosed is the use of the above composition for treating hyperphosphatemia, decreasing mortality rate in dialysis patients, treating metabolic acidosis, inhibiting calcium phosphate deposition, decreasing calcium-phosphorus product, decreasing serum calcium levels, reversing calcification of soft tissue, and aiding to dissolve a kidney stone. Also disclosed is the use of the above composition to treat a disorder characterized by a high serum phosphate level. |
